Nasus Pharma Ltd. · AMEX:NSRX
Nasus Pharma — Investor Presentation (June 2026)
44 slides from Nasus Pharma's investor presentation, Jun 9, 2026
Slide 1: A New Frontier in Intranasal Drug Delivery
NAasuUS PHARMA A NEW FRONTIER IN INTRANASAL DRUG DELIVERY: Aclinical-stage pharmaceutical eorhputl 4 leveraging its proprietary powder-based intranasal technology to develop innovative intranasal products Ticker NSRX Exchange NYSE American Company Presentation — June 2026
Slide 2: Forward Looking Statements; Disclaimer
Forward Looking Statements; Disclaimer This presentation of Nasus Pharma Ltd. (the “Company”, “Nasus” or “Nasus Pharma”) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities law. Words such as “expects,” “intends,” “pla
Slide 3: Company Highlights
Company Highlights Nasus is Uniquely Positioned to Transform Care via Intranasal Drug Delivery NS002 was designed to address limitations of injectable Epinephrine, with a needle-free, easy-to-administer product, and has already demonstrated in Phase 2 studies the potential for faster and higher abso
Slide 4: Robust Asset Pipeline Setting Up Potential for Long Term Growth
Robust Asset Pipeline Setting Up Potential for Long Term Growth Transforming Care via Intranasal Drug Delivery Drug Candidate Molecule Indication Preclinical Phase 1 Phase 2 Pivotal Trial Next Milestone Pivotal study conepnne spree ST expected tonite 4.2026 Ondansetron Nausea and Vomiting FIH study
Slide 5: Proprietary Nasax Platform Enables Superior Drug Absorption
Proprietary Nasax Platform Enables Superior Drug Absorption Powder formulation can reach all parts of nasal cavity; The greater intranasal absorption area enables faster delivery and higher maximal drug concentration compared to liquid formulations Liquid formulation fom @ Liquid Spray 7 . : . 7 ——
Slide 6: NS002: Intranasal Epinephrine
NSO002: INTRANASAL EPINEPHRINE
Slide 7: Anaphylaxis: A Time-Critical Medical Emergency
Anaphylaxis: A Time-Critical Medical Emergency Anaphylaxis is a severe allergic reaction; fatal in ~1% of cases" The standard of care for anaphylaxis is Epinephrine - this is typically self-administered via an Epinephrine auto-injector (EAl) or given via intramuscular (IM) injection by a healthcare
Slide 8: NS002 Designed to Address the Limitations of Intramuscular Epinephrine
NS002 Designed to Address the Limitations of Intramuscular Epinephrine The proposed solution: NS002 Product candidate aims to offer a needle-free solution, longer shelf-life, easily administered by trained professionals and patients alike, potentially delivering greater and faster drug absorption, p
Slide 9: Anaphylaxis: A Growing Opportunity in a Large Market
Anaphylaxis: A Growing Opportunity in a Large Market Estimated prevalence of anaphylaxis ~1-3% among ee eee of ~$2.3B Global Epinephrine market in 2024? +6.5% CAGR ~ atients with type 1 allergies in the U.S. rom 2010 to 20. Pati ith llergies in the U.S.? F 2 2023 Patients experience severe type | j
Slide 10: NS002: Clear Roadmap to NDA
NS002: Clear Roadmap to NDA ¢ Following FDA guidance based on the 505(b)(2) regulatory pathway * Demonstration of comparable PK/PD to EpiPen® only requirement for regulatory approval * Pivotal trial expected to initiate Q4 2026 * Short and cost-effective clinical development iv) iv) ‘eae 6 Initiate
Slide 11: The Competitive Landscape Indicates a Large and Expanding Opportunity for Needle-Free Epinephrine
The Competitive Landscape Indicates a Large and Expanding Opportunity for Needle-Free Epinephrine Orexo” Aquestive* ARS Pharma’ (Market Cap (Market Cap Market Cap $814.5M* ( BS ) SEK892M*) $491.6M*) PK Parameters Neffy (nasal spra’ fy ( prey) Ox640 ANAPHYLM Commercial (nasal powder) (sublingual) N=3
Slide 12: Market Research Shows Onset of Action is Important to Allergists
Market Research* Shows Onset of Action is Important to Allergists Speed of onset overwhelmingly Time to reach maximum epinephrine concentration e to therapeutic epinephrine threshold is important to physicians prescribing an impacts caregivers’ recommendation of epinephrine highly clinically meaning
Slide 13: NP007: Single and Repeated Dose Topline Analysis
NS002: NP0OO7: SINGLE AND REPEATED DOSE TOPLINE ANALYSIS
Slide 14: Study NP007: Designed to Compare Bioavailability, PK, PD and Safety
Study NP007: Designed to Compare Bioavailability, PK, PD and Safety of Single and Repeat Dosing with and without Nasal Allergic Challenge (NAC) t A Week 7: é Week 5: Nasal allergic 2xNS002 4mg MBEARcois challenge L+L nostril 2xNS002 4mg Week 1: Wee L+L nostril Group 1 Nasal allergic Week 2: Week 3:
Slide 15: Study NP007 Strengthens NS002's Potential to be Best in Class
Study NP007 Strengthens NS002’s Potential to be Best in Class Study confirms prior PK and safety findings, further demonstrating attributes of nasal powder technology: Rapid and high absorption of Epinephrine. NSO02 demonstrated faster absorption of epinephrine: * Shorter Tmax and T100 than EpiPen®.
Slide 16: NS002 Demonstrates Faster, Higher and Sustained Epinephrine Absorption
NS002 Demonstrates Faster, Higher and Sustained Epinephrine Absorption in Critical Therapeutic Window Geometric mean plasma epinephrine concentration over time (Baseline adjusted): NPO007 Ph2 topline analysis Single dose: Geometric mean, 1h (baseline adjusted, pg/mL) 50 OHA. NACHIN spray —O—B. en BA
Slide 17: NS002 Single Dose vs. EpiPen: Comparable Cmax and AUC, Shorter Tmax and T100
NS002 Single Dose vs. EpiPen®: Comparable Cmax (normal conditions) and AUC, Shorter Tmax and T100 Cmax (pg/mL) Geometric mean AUC (pg/mL*hr) Geometric mean 600 303 513.7 = 600 Cmax (pg/mL) poe 8S § o 8 8 re AUC (pg/mL* Bees s 4,5130.945.2 29.8 26.5 39.7 o om AUCO-10min ‘AUCO-30min auct Tmax (min.) 7
Slide 18: More Participants Achieved Epinephrine Threshold with NS002 compared to EpiPen
More Participants Achieved Epinephrine Threshold with NS002 compared to EpiPen® in the Critical Time Window Single dose: Proportion (%) who reached 100pg/mL Nsoo2 ees EpiPen® rime tiny | Mermel | ne mol] Merman 2.5 67.4% 65.3% 27.1% 0.0001 0.0002 5 88.4% 75.5% 64.6% 0.0081 10 95% 85.7% 89.6% - - 30
Slide 19: NS002 Pharmacodynamic Response Tracks EpiPen and Kept Within Normal Range
NS002 Pharmacodynamic Response Tracks EpiPen® and Kept Within Normal Range Median change from baseline - Systolic blood pressure (Single dose) 4s Baseline mm Hg (median): B = es E NAC+Nasus x1 EpiPen Nasus x1 %° Ss s 5 c 115.0 115.0 112.0 S 8: o = OA. NACH Nasus4mg 8. EpiPen —®=C. Nasus 4mg Median C
Slide 20: NS002 Pharmacodynamic Response Tracks EpiPen and Kept Within Normal Range
NS002 Pharmacodynamic Response Tracks EpiPen® and Kept Within Normal Range Median change from baseline- Heart rate (Single dose) 10 Sy 8 Baseline BPM (median): e 6 2 % bd NAC#Nasus x1 EpiPen Nasus x1 5 = 5 5 2 4 74.0 75.0 71.0 2 6 = Time (min.) « = O-A.NACHNasus dmg @=8.EpiPen —@=C. Nasus 4mg sus NA
Slide 21: Repeat Dosing Continues to Demonstrate Faster, Higher and Sustained Absorption
Repeat Dosing Continues to Demonstrate Faster, Higher and Sustained Absorption in a Dose Proportional Manner Normal conditions (baseline adjusted): NAC conditions (baseline adjusted): Geometric mean+SE, 0.5hr Geometric mean+SE, 0.5hr 1000 1000 4 900 i 900 4 _ 800 l cal ~ 800 4 | = 700 = 700 4 ‘i = =
Slide 22: NS002 Repeat Dosing Maintains Favorable PK Profile Observed with Single Dosing
NS002 Repeat Dosing Maintains Favorable PK Profile Observed with Single Dosing Tmax (min.) median os Cmax (pg/mL) Geometric mean 25 sais at p=0.022 ———— wae 40 19.8 19.8 19.8 1040.8 1088, a 1000.0 < 3 245.9 = as E00 g 15 5 oo S sooo z gee E 10 2 Fs 400.0 & rs 200.0 00 6 iil a catia Bi “i ate A. aero
Slide 23: Study NP007 Demonstrates that NS002 is Well Tolerated
Study NP007 Demonstrates that NS002 is Well Tolerated after Single and Repeat Administration (50 participants and 421 drug administrations) * No SAEs reported * NoCVAEs * Most AEs were local in nature and self resolving, with 95% mild and 5% moderate. * 1 participant discontinued due to eye pain. Ns
Slide 24: NP007: Summary and Conclusions
NP007: Summary and Conclusions NS002 demonstrated potential best-in-class attributes for epinephrine delivery NS002 reached the Epinephrine therapeutic plasma threshold significantly faster than EpiP conditions NS002 was well tolerated with transient mild symptoms; no SAEs or cardiovascular AEs 05 P
Slide 25: Strong Global IP Position
Strong Global IP Position Patent No./ Grant Date/ Status/Next action Expiration date Publication No. Pub. Date PCT PCT/IL2018/050914 | 19/08/2018 | WO 2019/038756 A1 National Phase entered 19/08/2038 Australia 2018319592 19/08/2018 2018319592 10/10/2024 Granted 19/08/2038 Canada 3,071,552 19/08/2018
Slide 26: Strong Global IP Position
Strong Global IP Position Patent No./ Grant Date/ Status/Next action Expiration date Publication No. Pub. Date USA 62/989,913 16/03/2020 Term Ended 16/03/2040 USA 17/135,528 28/12/2020 11,400,045 02/08/2022 Granted 28/12/2040 PCT PCT/IL2021/050288 | 16/03/2021] WO 2021/186437 | 23/09/2021 National P
Slide 27: Proprietary Nasax powder technology designed to enhance intranasal drug absorption
Proprietary Nasax powder technology designed to enhance intranasal drug absorption Lead product candidate NSO02 is needle-free, convenient, and easily administered; aiming to offer an alternative to Epinephrine autoinjectors and directly addressing the currently unmet need Multiple Phase 2 studies c
Slide 28: Leadership Team
Leadership Team Udi Gilboa, Co-Founder & Executive Chairman Mr. Gilboa is a prominent serial life sciences entrepreneur and the co-founder of multiple medical device and pharmaceutical companies. He co-founded and served as director and CFO of BioBlast Ltd (NASDAQ: ORPN), Alcobra Ltd (NASDAQ: ADHD),
Slide 29: A New Frontier in Intranasal Drug Delivery
NAasuUS PHARMA A NEW FRONTIER IN INTRANASAL DRUG DELIVERY: Aclinical-stage pharmaceutical eorhputl 4 leveraging its proprietary powder-based intranasal technology to develop innovative intranasal products to treat emergency medical conditions Ticker NSRX Exchange NYSE American
Slide 30: NP002
cription automatically [A white parti > Q =) =s WY) = O — ia . NPOO2
Slide 31: NS002 Single Dose vs. EpiPen: Comparable Cmax, Shorter Tmax and T100
NS002 Single Dose vs. EpiPen® : Comparable Cmax (normal conditions), Shorter Tmax and T100 Cmax (pg/mL) Tmax (min.) T100 (min.) Geometric mean median median 700.0 25 4 4 se 3.42 600.0 - 19.8 a 539.3 518.7 _ 20 _ i - = E 15 —E 55 =) 2 6 » £4000 aap § i S x 3 3 2 1.69 iS oc E 0 £ GS 3000 = 78 s 15 8 8
Slide 32: NP002: NS002 Pilot Study Overview
NP002: NS002 Pilot Study Overview Study goal: Test NS002’s Epinephrine bioavailability following allergenic challenge PK/PD measurements: plasma Epinepherine, Tmax, T100, AUC, SBP, HR 12 healthy adults with allergic rhinitis (9 male, 3 female) Screening: positive to skin allergen test Period 1 Day1
Slide 33: NP002: Faster, Higher and Sustained Absorption in Critical Therapeutic Window
NPOO2: Faster, Higher and Sustained Absorption in Critical Therapeutic Window Pilot Study Pharmacokinetics (PK) 700 600 Z 500 = 2 Plasma epinephrine - 2 400 —e-EpiPen 0.3 geometric mean —60 min. = —s-Nasus 1.6mg 3 =12 £€ 300 —e-Nasus 1.6mg+Allergen challenge = 8 —e-Nasus 3.2mg 8 200 —e-Nasus 3.2mgtA
Slide 34: NS002 vs. EpiPen: Shorter Tmax and T100 and Higher Absorption
NS002 vs. EpiPen®: Shorter Tmax and T100 and Higher Absorption Pilot study PK - baseline corrected time medians 20.00 15.00 10.00 Tmax (min.) 5.00 0.00 5.0 4.0 3.0 2.0 1.0 0.0 9.00 EpiPen 3.0 EpiPen Tmax median (min.) n=12 16.50 8.98 * i 5.99 Nasus1.6mg Nasus Nasus3.2mg —Nasus. 1.6mg+Allergic 3.2mg+
Slide 35: NS002 Pharmacodynamic Response Tracks EpiPen and Kept Within Normal Limits
NS002 Pharmacodynamic Response Tracks EpiPen® and Kept Within Normal Limits Pilot study pharmacodynamics (PD) Systolic Blood Pressure N=12 125 120 = “3 -e-EpiPen = 15 £ B <6 Nasus 1.6mg normal condition g ue —@—Nasus 1.6mg allergenic challenge 105 —@— Nasus 3.2mg normal condition 56 —@— Nasus 3.2mg
Slide 36: NP006: Phase 2 Single Dose Study
NS002: NPOO6: PHASE 2 SINGLE DOSE STUDY
Slide 37: NP006: NS002 Phase 2 Study Designed to Assess Safety and Tolerability
NPO0O6: NS002 Phase 2 Study Designed to Assess Safety and Tolerability of Single Dose Administration Arm 1: N=6 B Nasus spray 3.6mg jaggy asus spray 4.0mg On each dosing day: in one nostril in one nostril , Screening PK sampling: 12 healthy -1 to 2hr. (13 samples) Plasma Epinephrine, AUC, Cmax, Tmax
Slide 38: More Subjects Achieved Epinephrine Threshold with NS002 Compared to EpiPen
More Subjects Achieved Epinephrine Threshold with NS002 Compared to EpiPen® NPOO6 Phase 2 PK results Plasma Epinephrine Results 12 healthy subjects Comparison of Plasma Epinephrine (baseline adjusted) in Healthy Volunteers - Geometric 350 mean-30min 6min 30 EpiPen® 55 % 250 Nasus 3.6mg 72% —eNasus 4
Slide 39: NS002 Single Dose vs. EpiPen: Higher Cmax, Shorter Tmax and T100
NS002 Single Dose vs. EpiPen®: Higher Cmax, Shorter Tmax and T100 Phase 2 Results - Cmax, Tmax and T100pg/mL = a n=12 Cmax (Geometric mean + SD) n=12 Tmax (median, minutes) n=12 T100pg/mL (median, minutes) 1400 16 10 15 9 9 1200 14 8 12 = 1000 = > 7 E g 10 £ 2 = je E 6 ¥ 800 Fa S 5 Eos 5 Eos ‘= 600
Slide 40: NS002 Achieved Higher Absorption vs. EpiPen in the Critical Therapeutic Window
NS002 Achieved Higher Absorption vs. EpiPen® in the Critical Therapeutic Window Mean AUCO-4min +SD n=12 + Mean AUCO-10min +SD n=12 70 140 © 120 Es z 3 2 £ 100 Bao = 20 S20 27\44 o 63:96 : Zz 60 50199 PED 14la7 7 40 27/38 10 ae 20 ® Oo EpiPen Nasus 3.6mg Nasus 4.0mg = wane ans Phase 2 PK results sy a
Slide 41: NP006: NS002 Pharmacodynamic Response Tracks EpiPen and Kept Within Normal Limits
NPOO6: NSO02 Pharmacodynamic Response Tracks EpiPen® and Kept Within Normal Limits Systolic Blood Pressure n=12 Heart Rate n=12 140 90 = 120 85 Phase 2: E 20 % 80 pe 8 PD results 2 10 = 2 = & 100 70 65 90 0 20 40 60 go 100 120 co) 20 40 60 80 100 120 Tina (oan —EpiPen Time (min.) i n=12 Diastolic Bl
Slide 42: NP006: Results Summary
NPOO6: Results Summary NS002 Could Be a Compelling Alternative to Epinephrine Autoinjectors, with Faster, Greater and Well-Tolerated Epinephrine Delivery NS002 reached the Epinephrine therapeutic plasma threshold faster than EpiPen® No findings at nasal examinations No SAEs reported & . e study was
Slide 43: NS001: Intranasal Naloxone
NS001: INTRANASAL NALOXONE .
Slide 44: Pivotal Study Validated the Superiority of Powder over Liquid
Pivotal Study Validated the Superiority of Powder over Liquid, Demonstrating Nasax Platform Delivers Naloxone Faster Compared to Narcan® Mean AUC: 4,10 20 min Mean Plasma oo —e Nasus 30 25 20 1s Mean AUC hréng/ml 10 os Nasus Narcan Plasma Unconjugated Naloxone (ng/ml) 3 In our phase 3 (n=42) intrana